Reports Q3 revenue $2.7M, consensus $3.76M. “I’m grateful for the continued progress that we have seen across our late-stage pipeline, and I’m excited for the upcoming opportunity to serve patients with ATTR-CM in the commercial marketplace,” said Dr. Neil Kumar, Ph.D., CEO and Founder of BridgeBio (BBIO). “Underpinning this headway is a corporate experiment we have been conducting for over 9 years now that posits a new type of biotech business model, and so I’m also proud to have released our first case study in The Journal of Portfolio Management, highlighting salient elements of that model.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio announces publication on impact of biomedical innovation
- BBIO Upcoming Earnings Report: What to Expect?
- BridgeBio shares preliminary data from CANaspire Phase 1/2 trial of BBP-812
- BridgeBio price target lowered to $46 from $47 at Leerink
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls